Filipino Women Are Being Diagnosed With Cervical Cancer Too Late. HPV Vaccination Can Change That.

The Scale of the Problem in the Philippines

Cervical cancer is the third most common cancer among Filipino women according to GLOBOCAN 2024, the most recent global cancer estimates published by the IARC in July 2026, behind breast cancer and colorectal cancer. An estimated 7,829 new cases were diagnosed in 2024, with 3,389 deaths in the same year. The age-standardized incidence rate stands at 13.8 per 100,000 women. The disease particularly affects women aged 15 to 44, and approximately 25,215 Filipino women are currently living with cervical cancer within five years of diagnosis.

The five-year survival rate for cervical cancer in the Philippines has been estimated at 44 percent in pre-2024 analyses, reflecting the stage at which most women typically present to care. For context, countries with organized screening programs typically achieve five-year survival rates of 65 to 70 percent or higher, because they detect the disease at stages where treatment is most effective. The Philippine Commission on Women and Dr. Mary Ann Galang-Escalona of MSD Philippines stated explicitly in May 2025 that many women in the Philippines are diagnosed only when symptoms are already severe. Only an estimated 50 to 60 percent of those diagnosed receive any form of treatment, a figure shaped by a combination of geographic inaccessibility, cost, and late-stage presentation that makes curative treatment less feasible.

Why HPV Is at the Center of This

Approximately 99 percent of all cervical cancers are caused by persistent infection with high-risk strains of human papillomavirus, or HPV. HPV is a common sexually transmitted infection, and most people who contract it clear the virus naturally without developing any disease. In a small fraction of cases, particularly those involving HPV types 16 and 18, which are responsible for approximately 70 percent of cervical cancers globally, the infection persists and causes cellular changes in the cervix that, over years to decades without detection and treatment, progress to invasive cancer.

Research on the Philippine patient population confirms this pattern. Studies conducted locally found that HPV genotype prevalence among Filipino patients with cervical squamous cell carcinoma was 93.8 percent, and 90.9 percent among those with cervical adenocarcinoma. HPV types 16 and 18 were the most commonly detected genotypes. This means that the large majority of cervical cancer deaths in the Philippines are caused by a virus for which safe, effective vaccines have existed since 2006.

The Vaccination Gap

The HPV vaccine was included in the Philippines' National Immunization Program in 2015, making it available to Grade 4 female students through government channels. Despite this, coverage rates have remained critically low. A peer-reviewed analysis of the Philippine HPV vaccination program found that the country currently ranks last on HPV program coverage among low-middle income countries, with only 23 percent of the target female population completing the first dose and just 5 percent completing the final dose of the series. The principal barrier identified was the perceived high cost of vaccination outside the public program, combined with continuing hesitancy related to the Dengvaxia controversy that spilled over into vaccine acceptance more broadly after 2017.

The WHO's global strategy for cervical cancer elimination sets a target of vaccinating 90 percent of girls with the HPV vaccine by age 15 by 2030. The Philippines is far from that target. The IARC elimination planning tool calculates that without intervention, 446,020 women in the Philippines will die from cervical cancer between 2020 and 2070. If the country achieves the WHO's 90-70-90 targets by 2030, cervical cancer could be eliminated as a public health problem in the Philippines by 2062, and 970,469 lives would be saved by 2120. For every one US dollar invested in the combined vaccination and screening strategy, the estimated return is 22.32 US dollars to the economy over a 30-year period, rising to 66.71 US dollars over a 50-year timeframe when broader societal benefits are included.

The Screening Crisis

Vaccination addresses the upstream cause, but for the millions of women already past the optimal vaccination age, regular cervical screening is the primary tool for catching precancerous changes before they become invasive cancer. The Philippines has two widely available screening options: the Pap smear and visual inspection with acetic acid, or VIA, a lower-cost method where a dilute acetic acid solution is applied to the cervix and abnormal cells change color, making them visible to a trained health worker without laboratory equipment.

Despite the availability of these tools, screening uptake in the Philippines is among the lowest in the world. Only approximately 1 percent of Filipino women receive cervical or breast cancer screening annually, according to Manulife Philippines data citing global survey comparisons. The WHO recommends screening twice in a lifetime for women aged 35 and again at 45, a minimum frequency that would catch the majority of progressive lesions if consistently applied. DOH's National Integrated Cancer Control Program has committed to expanding access to screening services as part of its 2023-2028 strategic framework, but community-level delivery remains uneven.

• Women aged 21 to 65 who have ever been sexually active should discuss cervical screening with their doctor, regardless of HPV vaccination status
• Symptoms of cervical cancer, including abnormal vaginal bleeding, bleeding after sexual intercourse, unusual discharge, and pelvic pain, typically appear only in more advanced stages and should prompt immediate consultation
• HPV vaccination is most effective when given before sexual debut but remains beneficial for women who have not yet been exposed to HPV types 16 and 18
• PhilHealth's Z Benefit Package covers cervical cancer treatment including chemotherapy, radiotherapy, and surgery at accredited cancer centers